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OBJECTIVES Our objective in this research was the evaluation of the long-term results after directional
atherectomy using the Silverhawk device (FoxHollow Technologies, Redwood City, Cali-
fornia) of femoro-popliteal lesions.
BACKGROUND Considering reports on stent fractures in femoro-popliteal arteries, atherectomy may be a
valuable alternative to stenting.
METHODS Eighty-four patients with 100 legs and 131 lesions with peripheral occlusive disease
Rutherford categories 2 to 5 were included in a prospective registry. Forty-five lesions were
de novo lesions (group 1; 34%), 43 lesions native vessel restenoses (group 2; 33%), and 43
lesions in-stent restenoses (group 3; 33%). Additional low pressure balloon angioplasty was
used in 78 of 131 lesions (59%) and stenting in 8 lesions (6%).
RESULTS Technical success rate was 86% for atherectomy only and 100% after additional therapy.
Mean lesion length was 43 54 mm, 105 122 mm, and 131 111 mm for group 1, group
2, and group 3, respectively (p  0.001). Primary patency, defined as freedom of a 50%
restenosis detected by duplex, was 84%, 54%, and 54% at 12 months (p  0.002) and 73%,
42%, and 49%, at 18 months (p  0.008); secondary patency rates were 100%, 93%, and 91%
at 12 months (p  NS) and 89%, 67%, and 79% at 18 months (p  0.001), respectively; and
target lesion revascularization rate was 16%, 44%, and 47% at 12 months and 22%, 56%, and
49% at 18 months (p  0.003 each) for group 1, group 2, and group 3, respectively. The only
independent predictor for restenosis was treatment of restenotic lesions. Ankle-brachial index
was significantly improved after 12 months and 18 months in all groups.
CONCLUSIONS Long-term technical and clinical results after directional atherectomy of femoro-popliteal
lesions are in favor of de novo lesions compared with restenotic lesions. (J Am Coll Cardiol


















1alloon angioplasty of femoro-popliteal lesions is limited by
low primary patency rate of 30% to 61% after 3 years
epending on lesion length and clinical stage (1–5). Stent-
ng initially resulted in disappointing long-term results with
-year primary patency rates of 22% for the balloon-
xpandable Palmaz stent (Cordis Corp., Haan, Germany)
6) and of 30% for the self-expanding Wallstent (Boston
cientific, Natick, Massachusetts) (7); the primary patency
ad been substantially improved to 61% for the SMART
itinol stent (Cordis Corp.) (7,8). However, the patency
ate of nitinol stents seems to be dependent on the type of
tent implanted (8,9). Another not yet completely under-
tood issue is the impact of stent fractures on long-term
atency and formation of pseudoaneurysms (8,9). Percuta-
eous removal of obstructive material through directional
therectomy represents a theoretical approach for reducing
estenosis rate. Whereas older single-center studies with the
impson Atherocath report high primary success rates and
cceptable long-term results for the treatment of femoro-
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asel, Switzerland; and the ‡Department of Diagnostic and Interventional Radiology,
niversity Hospital Tübingen, Tübingen, Germany.2
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ccepted July 3, 2006.opliteal lesions (10–14), 2 randomized trials found similar
esults as for conventional balloon angioplasty (15,16). This,
long with the demanding technique, prevented atherec-
omy to become established as a routine technique. The
ntroduction of the easy-to-use Silverhawk device (FoxHol-
ow Technologies, Redwood City, California) has re-
stablished the use of directional atherectomy with prom-
sing acute technical and clinical success rates and mid-term
atency rates for the treatment of femoro-popliteal lesions
17,18). Nevertheless, long-term data are still lacking.
We here report the prospective single-center long-term
esults after treatment of femoro-popliteal lesions with the
ilverhawk atherectomy catheter (FoxHollow Technologies).
ETHODS
n this prospective single-center study between June 2002
nd May 2004, 84 patients with femoro-popliteal lesions
ith chronic peripheral occlusive disease (POD) Rutherford
ategories 2 to 5 were treated with directional atherectomy.
The following inclusion criteria were prospectively defined:
. Stable chronic POD (e.g., no change of the Rutherford
category during the last 3 months before study inclu-
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. No complete intraluminal calcification in the lesion
detected by pre-interventional ultrasound.
e excluded patients with acute occlusions and/or with
ngiographically visible thrombus.
The study was approved by the local ethics committee,
nd all patients gave written informed consent to partici-
ate.
A 7-F sheath (Avanti, Cordis; or Balkin, Cook, Bjaever-
kov, Denmark) that is compatible with a monorail-guided
therectomy catheter (Silverhawk P4010 or P4011 debulk-
ng catheter, FoxHollow) was used. The target vessels
ncluded superficial femoral artery (SFA; n  86), popliteal
rtery (n  30), and lesions including the distal SFA and
roximal popliteal artery (n  15), which were counted as 2
esions (SFA and popliteal artery). Forty-five lesions were
e novo lesions (group 1; 34%), 43 lesions native vessel
estenoses (group 2; 33%), and 43 lesions in-stent restenoses
group 3; 33%). One, 2, 3, or 4 lesions were treated in 74,
3, 2, and 1 limbs, respectively. Thirty-six patients were
iabetic patients (43%) (Table 1). Angiographic measure-
ents of the vessel and lesion diameters were performed
sing the automated contour detection program of the an-
iography unit (Angiostar and Multistar, Siemens, Erlangen,
ermany). Based on these measurements, the degree of the
iameter stenosis was calculated.
The pre- and post-interventional (before discharge, after
, 12, and 18 months) diagnostics included, in addition to a
linical examination, the Doppler occlusive pressure mea-




ale gender (%) 80
ge (yrs) 63  9




FA (n)* 39 (87%)
opliteal artery (n)* 6 (13%)
esion length (mm) 43  54
eference diameter (mm) 5.12  1.03
LD (mm) 0.80  0.60
iameter stenosis (%) 85  11
BI at baseline 0.60  0.19
Abbreviations and Acronyms
ASA  acetylsalicylic acid
MLD  minimal lumen diameter
POD  peripheral occlusive disease
SFA  superficial femoral artery
TALON  Treating peripherALs with silverhawk:
Outcomes collectioN registryIncluding lesions lasting from the distal SFA to the popliteal artery counted as SFA and
ABI  ankle brachial index; MLD  minimal lumen diameter; SFA  superficial femurement with a calculation of the ankle-brachial index,
olor duplex sonography, and the determination of routine
aboratory parameters. Restenosis definition was based on
uplex ultrasound with a 50% restenosis defined as a
roximal systolic peak flow velocity ratio2.4 (17). Clinical
mprovement was expressed as difference in Rutherford
lasses after 18 months.
All lesions were treated primarily with the Silverhawk
atheter (FoxHollow Technologies). The number of lesion
asses was left to the discretion of the interventionist. The
atheter function of the 0.014-inch wire-guided device had
lready previously been described (18,19). The 7-F sheath-
ompatible device was designed for the treatment of vessel
iameters of 3 to 7 mm. The use of an additional low
ressure balloon was left to the discretion of the interven-
ionist. However, the balloon pressure should not exceed 3
tm. Stenting was discouraged and only allowed with
ow-limiting dissection (bail out indication) or a residual
tenosis after atherectomy and low-pressure balloon angio-
lasty.
edical therapy. Post-interventional therapy consisted of
cetylsalicylic acid (ASA), 100 mg/day for life, and clopi-
ogrel, 75 mg/day, for 4 weeks. The antiplatelet therapy was
tarted at the latest the day before the intervention with a
oading dose of clopidogrel of 600 mg and 500 mg of ASA.
eri-interventional administration of 2,500 to 5,000 inter-
ational units of heparin was given intra-arterially after
heath placement. The dose of heparin was depending on
he length of the intervention; after sheath placement, a
olus of 2,500 international units was given and repetitively
dministered if the intervention extended 1 h. None of the
nterventions in this study lasted longer than 2 h, so that the
aximum heparin dose was 5,000 international units. Ac-
ivated clotting time (ACT) measurement was not done
outinely.
tatistics and definitions. For continuous variables, values
re given as the average value  SD, and for discrete




In-Stent Restenoses p Value
43 43 0.60
50 58 0.044





2 (64%)* 32 (63%)* 0.27
8 (36%)* 19 (37%)* 0.003
05  122 131  111 0.001
90  0.7 4.94  0.66 0.096
67  0.60 0.74  0.74 0.78
87  11 88  9 0.50
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October 17, 2006:1573–8 Long-Term Results of Directional Atherectomyercent. Comparisons were made using analysis of variance,
hi-square test, and Fisher exact test as appropriate. Anal-
ses were by lesion except the Kaplan-Meier event-free
urvival curves for survival without target vessel revascular-
zation. All hypothesis testing was 2-tailed, and a value of
 0.05 was considered significant. Kaplan-Meier analysis
as applied to calculate cumulative long-term survival. Cox
egression analysis was used to identify independent predic-
ors of restenosis. Variables associated with restenosis in
nivariable analysis with a value of p  0.05 were entered
nto the multivariable model.
Technical success after atherectomy was defined as50%
esidual stenosis; procedural success was defined as 30%
esidual stenosis. Primary patency is defined as freedom of
estenosis 50% calculated by duplex ultrasound without
ny reintervention at the level of the target lesion at the time
f follow-up visit. Secondary patency is defined as freedom
f restenosis 50% at the time of follow-up visit after
eintervention in case of restenosis or reocclusion of the
arget lesion before the follow-up visit. The indication for
arget lesion revascularization rate was exclusively driven by
ecurrent symptoms. Change of ankle brachial index or a
ise in peak velocity ratio detected by duplex ultrasound only
ithout concomitant life-style–limiting symptoms or recur-
ent critical limb ischemia did not lead to reintervention.
ESULTS
total of 84 patients (64% male patients, mean age 66  12
ears, range 40 to 88 years) with 100 lower limbs and 131
emoro-popliteal lesions were entered into this study. Patients’
aseline characteristics are shown in Table 1. Total occlusions
ere treated in 8.5%. The average lesion length was 90 106
m (range 10 to 400 mm) with significantly longer lesions in
roups 2 and 3 (Table 2). Mean lesion length was 43  54
m, 105  122 mm, and 131  111 mm for group 1, group
, and group 3, respectively (p  0.001; Table 2). Technical
nd procedural success was achieved in all interventions ac-
ording to the prospectively defined criteria. After atherectomy
lone, in 126 of 131 (96%) lesions, residual stenosis was50%
technical success), and in 100 of 131 (76%) residual stenosis
as 30% (procedural success). Additional low pressure bal-
oon angioplasty using a balloon catheter sized adequately to
he reference vessel diameter with maximum 4 atms of pressure
pplied by an in-deflator was performed in 78 of 131 lesions
able 2. Acute Results, Subgroup Analysis
Group 1,
De Novo Lesions
LD post-atherectomy (mm) 3.86  0.95
S post-atherectomy (%) 26  17
LD final (mm) 4.58  0.68
S final (%) 14  9
alloon angioplasty 25/45 (56%)
tenting (%) 1/45 (2%)
BI before discharge 0.90  0.17BI  ankle brachial index; DS  diameter stenosis; MLD  minimal lumen diameter.59%) and stenting in 8 lesions (6%). The reason for low
ressure after dilatation was either to achieve procedural
uccess (24%) or the angiographic appearance of haziness
ithout a focal residual stenosis with the goal of smoothing the
essel surface with balloon angioplasty. Stent implantation was
ndicated in 1 case of a type C dissection after post-dilatation;
n another case, an already pre-interventionally detected stent
racture of a previously implanted stent led to a stent-in-stent
lacement. In the remaining cases, residual stenoses of
bout 50% after additional balloon angioplasty due to
eavily or eccentric calcification prompted stent implanta-
ion.
The mean percent diameter stenosis for the entire study
ohort was 87  10% with an average minimal lumen
iameter (MLD) of 0.73  0.65 mm (mean angiographic
roximal reference vessel diameter: 5.0 0.69 mm) without
ignificant difference between the 3 subgroups (Table 2).
he average percent diameter stenosis after atherectomy
as reduced from 87  10% (range 70% to 100%) to 27 
7% (range 0% to 100%), and the MLD increased from
.88  0.7 mm to 3.7  0.9 mm (range 0 to 5.5). After
dditional balloon dilatation or stent implantation, the
ercent diameter stenosis further decreased to 12  10%
0% to 30%), and the final MLD was 4.5  0.8 mm (range
.6 to 5.5 mm). The procedural outcome data stratified for
he 3 subcohorts are plotted in Table 2.
Twelve- and 18-month follow-up was complete for all
urviving patients (n  81) (Fig. 1). Three patients died
uring follow-up, 1 because of prostate cancer, 2 patients
ue to myocardial infarction.
Primary patency was 84%, 54%, and 54% at 12 months
p  0.002) and 73%, 42%, and 49% at 18 months (p 
.008) for group 1, group 2, and group 3, respectively.
econdary patency rates were 100%, 93%, and 91% at 12
onths (p  NS) and 91%, 65%, and 76% at 18 months (p
0.001), respectively. Target lesion revascularization rate
as 16%, 44%, and 47% at 12 months (p 0.003) and 22%,
4%, and 49% at 18 months (p  0.003) for group 1, group
, and group 3, respectively (Table 3). Figure 2 shows the
aplan-Meier event-free survival curves for survival without
arget vessel revascularization.
Multivariable regression analysis identified the treatment





In-Stent Restenoses p Value
3.76  0.74 3.59  1.1 0.40
25  15 29  19 0.51
4.58  0.69 4.38  0.89 0.53
9  8 13  13 0.06
28/43 (65%) 28/43 (65%) 0.6
3/43 (7%) 4/43 (9%) 0.4
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Long-Term Results of Directional Atherectomy October 17, 2006:1573–8Compared with baseline, the ankle-brachial index was
ignificantly improved after 12 months and 18 months in all
roups (group 1: 0.60  0.19 vs. 0.80  0.20 vs. 0.77 
.27 [p  0.001]; group 2: 0.52  0.22 vs. 0.70  0.35 vs.
.74 0.23 [p  0.001]; group 3: 0.58  0.38 vs. 0.80 
.29 vs. 0.79  0.35 [p  0.001]) (Table 4).
Changes in at least 2 Rutherford categories after 18
onths were significantly more frequently found for pa-
ients in group 1 compared with groups 2 and 3, respec-
ively, despite the fact that there was no significant differ-
nce in ankle-brachial index at 18 months (Table 4). No
atient of group 1 underwent major amputation, whereas 1
atient of group 2 and 2 patients of group 3 underwent
elow-the-knee amputation during follow-up (Table 3).
here was no difference in bypass graft frequency among the
groups (p  0.722) (Table 4).
omplications. During the first 8 interventions, 5 periph-
ral emboli of atherectomized wall components were ob-
erved. They could be completely removed by aspiration
ith a 5-F or 6-F aspiration catheter in a single aspiration
aneuver. The embolized material came out each time
Figure 1. Study profile.
able 3. Univariable and Multivariable Analysis of Predictors of
Univariable Analysis
HR Lower 95% CI Upper 95
ative vessel restenosis 3.904 1.575 9.68
n-stent restenosis 3.238 1.309 8.00
ean reference vessel diameter 0.392 0.216 0.71
ean lesion length 1.005 1.002 1.00
iameter stenosis at baseline 1.064 1.023 1.10
LD at baseline 0.270 0.128 0.57
ge 0.983 0.943 1.02
BI at baseline 0.392 0.088 1.75
ypercholesterolemia 2.873 0.573 14.39
moking 1.169 0.521 2.62
iabetes 0.714 0.355 1.43
ypertension 0.646 0.233 1.79BI  ankle brachial index; CI  confidence interval; HR  hazard ratio; MLD  minhrough the small vent hole near the end of the catheter tip.
fter the catheter tip was emptied after no more than 4
assages through stenosed areas and the reservoir was
echnically modified, there were no further emboli. A type
dissection after additional balloon dilatation had to be
reated with a stent (SMART control, Cordis). There were
0 occasions where the blade became temporarily bound
hile in the forward position in the catheter tip (reservoir).
his occurred only when the vessel had a bend or turn; it
appened 6 times during cross-over application of the
evice. The blade could always be freed by turning the
ocking rotator. No vessel wall perforation was observed.
ISCUSSION
e report on the long-term results of a prospective cohort
f patients with femoro-popliteal lesions treated with the
ilverhawk directional percutaneous atherectomy catheter
ystem (FoxHollow Technologies). Initial acute and mid-
erm results reported promising results comparable to the
utcome of nitinol stents in the same vessel area (19).
igure 2. Kaplan-Meier event-free survival curves for survival without
arget vessel revascularization.
nosis After Directional Atherectomy
Multivariable Analysis
p Value HR Lower 95% CI Upper 95% CI p Value
0.003 2.34 1.08 5.06 0.031
0.011 2.59 1.19 5.65 0.017
0.002 0.70 0.45 1.10 0.123
0.004 1.001 0.998 1.003 0.621
0.002 0.95 0.87 1.04 0.306









































































































1577JACC Vol. 48, No. 8, 2006 Zeller et al.
October 17, 2006:1573–8 Long-Term Results of Directional AtherectomyCompared with the Simpson Atherocath that was not
stablished for treatment of femoro-popliteal lesions in the
arly 1990s because of its complex operation and missing
uperiority over balloon angioplasty (10–16), the Silver-
awk system (FoxHollow Technologies) is simple to oper-
te and therefore could contribute to a rebirth of directional
therectomy.
Atherectomy alone, in the majority of cases (97%), led to
echnical success defined as 50% residual stenosis; addi-
ional balloon dilatation in most cases served to visually
mprove the appearance with clarified stenosis contours; in
4% balloon angioplasty was necessary to reach the prospec-
ively defined procedural success (30%). Thus, the initial
se of the system tested here is more successful than that of
he old Simpson Atherocath, reporting primary success rates
f 82% to 100% (12,20). Additional stent implantation was
ndicated only in a minority of lesions.
The only 2 randomized comparative studies for the
reatment of femoro-popliteal lesions between atherectomy
ith the Simpson Atherocath and balloon dilatation were
ot able to demonstrate any advantage for atherectomy
15,16), however, individual single-center studies showed
ositive long-term results (10–14,20–24). In our study
ohort, long-term results are encouraging considering the
act of including mostly challenging lesions into the study.
he best outcome results were found for de novo lesions
ith 12- and 18-month primary patency rates of 84% and
3%, respectively. However, also for in-stent restenotic
esions, primary 12-month patency rate is higher than
eported for a rotational thrombectomy device (Straub-
otarex, Straub Medical, Wangs, Switzerland, 54% vs. 31%
25]), which also atherectomizes neointima if the device
ets in direct contact with the vessel wall.
Despite a significantly shorter mean length of the de novo
esions, multivariable analysis identified restenotic lesion,
egardless of whether native vessel or in-stent restenosis was
he only independent predictor of restenosis.
The results presented here are not comparable with the
ulticenter TALON (Treating peripherALs with silver-
able 4. Long-Term Results Subcohort Analysis Per Lesion
Group 1,
De Novo Lesions
rimary patency 12 months (%) 84
econdary patency 12 months (%) 100
LR 12 months (%) 16
BI 12 months 0.80  0.20
rimary patency 18 months (%) 73
econdary patency 18 months (%) 91
LR 18 months (%) 22
BI 18 months 0.77  0.27
mprovement of 2 Rutherford categories
at time of latest follow-up
84%
ypass surgery 3/31 limbs (9.7%)
mputation (n) 0
BI  ankle brachial index; TLR  target lesion revascularization.awk: Outcomes collectioN) Registry. In this registry, a aixed cohort of lower extremity lesions including iliac
rteries, femoro-popliteal arteries, and below-the-knee ves-
els were analyzed regarding freedom of target vessel revas-
ularization rate reporting 90% and 80% at 6 months and 12
onths, respectively. However, the results of the TALON
egistry (26) are not based on any objective imaging
echniques like duplex ultrasound, intra-arterial or magnetic
esonance, or computed tomography angiography to deter-
ine the real restenosis rate.
The major finding of this study is that atherectomy of de
ovo femoro-popliteal lesions with the Silverhawk catheter
FoxHollow Technologies) achieves comparable 1-year
16%) and 18-month (27%) binary restenosis rates com-
ared with stenting using current bare and drug-coated
itinol stents. The SIROCCO (Sirolimus-Eluting versus
are Nitinol Stent for Obstructive Superficial Femoral
rtery Disease) Trial (27) currently representing the most
avorable outcome data for nitinol stents in the SFA
omparing the result of the treatment of de novo SFA
esions with bare SMART nitinol stents (Cordis Corp.) and
irolimus-coated SMART stents, respectively, resulted in a
inary restenosis rate at 18 months of 18% and 21%,
espectively. The data regarding the good 1-year perfor-
ance of the SMART nitinol stent are confirmed by the
egistry data of Scheinert et al. (9) (and unpublished data
resented at Transcatheter Cardiovascular Therapeutics,
004) who found a 1-year primary patency of 82% for this
articular stent type. However, 2 other prospectively exam-
ned stent types had less favorable 1-year primary patency
ates of 44% (7-F SelfEx, Abbott-Jomed, Redwood City,
alifornia) and 27% (Luminexx, Bard, Murray Hill, New
ersey), respectively, which are considerably lower compared
ith those we have found for directional atherectomy.
Considering the still unresolved issue of stent fractures
fter SFA and popliteal artery stenting (8,9,28), any tech-
ology that improves the acute technical result of angio-
lasty avoiding stenting should be beneficial. Atherectomy
otentially reduces barotraumas—vessel wall injury from












0.74  0.23 0.79  0.35 0.87
53% 62% 0.027
6/38 limbs (15.8%) 4/31 limbs (12.9%) 0.722
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Long-Term Results of Directional Atherectomy October 17, 2006:1573–8Limitations of this study are the mixed study population
egarding inclusion of de novo lesions, restenotic non-
tented and stented vessel segments, and the inclusion of
FA and popliteal artery lesions. Furthermore, this is not a
andomized study including a reference group undergoing
alloon angioplasty. Further studies have to examine the
est use of the Silverhawk (FoxHollow Technologies)
therectomy device regarding long-term patency: plain
therectomy to avoid barotrauma induced by additional
alloon angioplasty or atherectomy combined with balloon
ngioplasty to achieve the best acute MLD. Furthermore, it
ould be of interest if an intravascular-ultrasound-guided
ptimized atherectomy technique would achieve better
ong-term patency results than reported in the present
tudy.
eprint requests and correspondence: Dr. Thomas Zeller, De-
artment of Angiology, Herz-Zentrum Bad Krozingen, Südring
5, D-79189 Bad Krozingen, Germany. E-mail: thomas.zeller@
erzzentrum.de.
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